This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

3 Aug 2012

Merck Serono Creates New Spin-off Company

Merck Serono's first spin-off company under its Entrepreneur Partnership Programme will focus on Parkinson's disease.

Merck Serono has announced the creation of the first spin-off company from its Entrepreneur Partnership Programme, which was launched in April 2012.


Prexton Therapeutics is backed by initial funding of EUR2.1 million from Merck Serono and will focus on programmes targeting the metabotropic glutamate receptors mGluR3 and mGluR4 in Parkinson's disease.


The new company will be staffed by experienced Merck Serono scientists and will concentrate on a portfolio of chemical compounds from the company's earlier pre-clinical research.


Based in Geneva, Prexton will take compounds up to phase-I clinical development, before seeking partnership and licensing opportunities.

Related News